Hereditary Inclusion Body Myopathy (h-IBM) – Drugs In Development, 2024
Powered by ![]()
Unlock hidden opportunities in the Pharmaceuticals industry
Empower your strategies with our Hereditary Inclusion Body Myopathy (h-IBM) – Drugs In Development, 2024 report and make more profitable business decisions.
Hereditary inclusion body myopathy (h-IBM) is a rare, adult-onset muscle disorder. It is characterized by severe, progressive muscle weakness. Symptoms of IBM vary, but usually include progressive weakness in the muscles of the hand, forearm, thigh, and lower leg. Physical examination and medical history, blood tests to look for disease-specific enzymes or antibodies, nerve conduction studies to measure any interruptions in the nerve signal, electromyography to help rule out neurological conditions, muscle biopsy to verify the presence of inclusion bodies, and genetic testing are useful to confirm the diagnosis. Treatment options include physical and occupational therapy and speech therapy.
The Hereditary Inclusion Body Myopathy (h-IBM) drugs in development market research report provide comprehensive information on the therapeutics under development for Hereditary Inclusion Body Myopathy (h-IBM), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action and product description of the therapeutics, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Hereditary Inclusion Body Myopathy (h-IBM) and features dormant and discontinued products.
Note:
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase.
* Certain sections in the report may be removed or altered based on the availability and relevance of data.
| Quick View – Hereditary Inclusion Body Myopathy (h-IBM) | Key Targets |
|
|
| Key Mechanisms of Action |
|
||
| Key Routes of Administration |
|
||
| Key Molecule Types |
|
||
| Major Companies |
|
||
Scope
- Therapeutics in Development: Covering 5 molecules, with 5 developed by companies and the rest by universities/institutes.
- Analysis Parameters: Offering insights by stage of development, drug target, MoA, RoA, and molecule type for a comprehensive overview.
- Pharmacological Insights: Understand the descriptive pharmacological action of therapeutics.
- Development History: Access the complete research and development history.
- Latest News and Press Releases: Stay updated with the latest developments through comprehensive news coverage.
Reasons to Buy
- Holistic insights: Understand the broad spectrum of Hereditary Inclusion Body Myopathy (h-IBM) therapeutics, aiding strategic decision-making with insights into stages, targets, MoA, RoA and molecule types.
- Pipeline Exploration: Explore the detailed Hereditary Inclusion Body Myopathy (h-IBM) pipeline, offering nuanced analysis of drug targets, mechanisms of action and routes of administration for varied decision-making.
- Comprehensive R&D: Access thorough R&D histories, providing a comprehensive understanding of Hereditary Inclusion Body Myopathy (h-IBM) treatments for adaptable decision-making.
- Save valuable hours: Identify key players steering innovation in therapeutics, enabling strategic partnerships.
Key Players
Gradalis IncNobelpharma Co Ltd
Orphina Biotechnology
Table of Contents
Table
Figures
Frequently asked questions
Related reports
View more Hereditary Inclusion Body Myopathy (h-IBM) reports